Kadimastem Ltd Asset Resilience Ratio
Kadimastem Ltd asset resilience ratio. Kadimastem Ltd (KDST) has an Asset Resilience Ratio of 16.66% as of September 2016. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read KDST current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Kadimastem Ltd (2013–2015)
Asset resilience ratio of Kadimastem Ltd from 2013 to 2015. This chart shows how Kadimastem Ltd's Asset Resilience Ratio has changed over time. See KDST free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Kadimastem Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see KDST asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA1.20 Million | 16.66% |
| Total Liquid Assets | ILA1.20 Million | 16.66% |
Asset Resilience Insights
- Good Liquidity Position: Kadimastem Ltd maintains a healthy 16.66% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Kadimastem Ltd Industry Peers by Asset Resilience Ratio
Compare Kadimastem Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Kadimastem Ltd Asset Resilience Ratio by Year (2013–2015)
Kadimastem Ltd asset resilience ratio by year from 2013 to 2015. The table below shows the annual Asset Resilience Ratio data for Kadimastem Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2015-12-31 | 31.57% | ILA2.50 Million ≈ $6.70K |
ILA7.92 Million ≈ $21.23K |
-24.87pp |
| 2014-12-31 | 56.45% | ILA6.79 Million ≈ $18.20K |
ILA12.02 Million ≈ $32.24K |
+0.90pp |
| 2013-12-31 | 55.55% | ILA6.89 Million ≈ $18.48K |
ILA12.41 Million ≈ $33.27K |
-- |
About Kadimastem Ltd
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a cli… Read more